Diagnostic delay in psoriatic arthritis: insights from a nationwide multicenter study
View/ Open
Access
info:eu-repo/semantics/closedAccessDate
2023Author
Kılıç, GamzeKılıç, Erkan
Tekeoğlu, İbrahim
Sargın, Betül
Cengiz, Gizem
Balta, Nihan Cüzdan
Alkan, Hakan
Kasman, Sevtap Acer
Şahin, Nilay
Orhan, Kevser
Gezer, İlknur Albayrak
Keskin, Dilek
Mülkoğlu, Cevriye
Reşorlu, Hatice
Ataman, Şebnem
Bal, Ajda
Duruöz, Mehmet Tuncay
Küçükakkaş, Okan
Şen, Nesrin
Toprak, Murat
Yurdakul, Ozan Volkan
Melikoğlu, Meltem Alkan
Ayhan, Fikriye Figen
Baykul, Merve
Bodur, Hatice
Çalış, Mustafa
Çapkın, Erhan
Devrimsel, Gül
Hizmetli, Sami
Kamanlı, Ayhan
Keskin, Yaşar
Ecesoy, Hilal
Kutluk, Öznur
Şendur, Ömer Faruk
Tolu, Sena
Tuncer, Tiraje
Nas, Kemal
Metadata
Show full item recordCitation
Kılıç, G., Kılıç, E., Tekeoğlu, İ., Sargın, B., Cengiz, G., Balta, N. C., Alkan, H., Kasman, S. A., Şahin, N., Orhan, K., Gezer, İ. A., Keskin, D., Mülkoğlu, C., Reşorlu, H., Ataman, Ş., Bal, A., Duruöz, M. T., Kücükakkaş, O., Şen, N., Toprak, M., … Nas, K. (2023). Diagnostic delay in psoriatic arthritis: insights from a nationwide multicenter study. Rheumatology international, 10.1007/s00296-023-05479-z. Advance online publication. https://doi.org/10.1007/s00296-023-05479-zAbstract
This study aimed to investigate the duration of diagnostic delay in patients with psoriatic arthritis (PsA) and identify potential contributing factors using a comprehensive, population-based approach. Data were obtained from the Turkish League
Against Rheumatism (TLAR)-Network, involving patients who met the CASPAR criteria. Diagnostic delay was defned as
time interval from symptom onset to PsA diagnosis, categorized as≤2 years and>2 years. Temporal trends were assessed
by grouping patients based on the year of diagnosis. Various factors including demographics, clinical characteristics, disease
activity, quality of life, physical function, disability, fatigue, and well-being were examined. Logistic regression models
were used to identify factors associated with diagnostic delay. Among 1,134 PsA patients, mean diagnostic delay was 35.1
months (median: 12). Approximately 39.15% were diagnosed within 3 months, and 67.02% were diagnosed within 24
months. Patients experiencing longer delays had higher scores in Psoriatic Arthritis Quality of Life Questionnaire (PsAQoL),
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), patient’s global assessment (PtGA) and physician’s global assessment (PhGA). Diagnostic delay has
decreased over time, with median delay falling from 60 to 24 months throughout pre-2010 and 2015–2019 terms. Several
factors were identifed as signifcant contributors to delayed diagnosis, including lower levels of education (OR=2.63),
arthritis symptoms preceding skin manifestations (OR=1.72), low back pain at frst visit (OR=1.60), symptom onset age
(OR=0.96), and psoriasis subtype (OR=0.25). Timely diagnosis of PsA is crucial for efective management and improved
outcomes. Despite recent improvements, about one-third of PsA patients still experience delays exceeding 2 years. By identifying infuential factors such as education level, arthritis symptoms preceding skin manifestations, initial visit symptoms,
age of symptom onset, and psoriasis subtype, healthcare practitioners may create specifc techniques to help in early detection and intervention